Vaccine and biotechnology company Abera Bioscience has, together with Radboud University Medical Center, submitted an application to the Dutch Medicines Authority to begin a clinical phase I study with the vaccine candidate Ab-01.12. This is according to a press release.The application includes the documentation required ahead of the authorities' review. Subject to the necessary regulatory approvals being obtained, the aim is to begin the study in autumn 2026."After the authorities' review and the required approvals, we look forward with confidence to beginning the first clinical study with Ab-01.12," says CEO Maria Alriksson.